Sad to say, your comments are an accurate reflection of reality. The Board and the CEO of this company have hd a nice old time travelling business class and staying at some nice hotels at our expense. It is time to cut up the corporate credit card.
I recommend shareholders call an EGM and get rid of the lot - including the latest Board addition - given his dearth of biotech expertise. If the product is really that good, then lets appoint a sensible investment bank to find a buyer and hang on for a capital return and the drip feed of some royalties.
We were stupid to believe in the CEO's "outsource everything" business model as it simply entrenched his as indispensable because he was the only one carrying the relevant phone numbers - and only he knew "where the bodies are buried" so nobody could go around him to discuss concerns with the Board - if they really cared anyway.
Morgans have some explaining to do as well in my opinion....................Not happy Jan.
TIS Price at posting:
12.0¢ Sentiment: None Disclosure: Held
